

FILE 'HCAPLUS' ENTERED AT 12:54:19 ON 21 APR 2005

E ACETYL-TYROSINE

E ACETYL TYROSINE

L18 85 S ACETYL TYROSINE

FILE 'HCAPLUS' ENTERED AT 12:59:55 ON 21 APR 2005

L19 85 S L18

L20 1 S L9 AND (FOOD OR SUPPLEMENT OR DIET?)

=> d stat que

L9 2 SEA FILE=HCAPLUS ABB=ON PLU=ON "HALEVIE GOLDMAN  
BRIAN D"/AU

L20 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND (FOOD OR  
SUPPLEMENT OR  
DIET?)

=> d stat que nos

L9 2 SEA FILE=HCAPLUS ABB=ON PLU=ON "HALEVIE GOLDMAN  
BRIAN D"/AU

L20 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND (FOOD OR  
SUPPLEMENT OR  
DIET?)

=> d ibib abs hitrn l20 tot

L20 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:11098 HCAPLUS

DOCUMENT NUMBER: 136:64168

TITLE: Compositions and methods for the production of  
S-adenosylmethionine within the body

INVENTOR(S): \*\*\*Halevie-Goldman, Brian D.\*\*\*

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002002146	A1	20020103	US 2001-781822	20010212
PRIORITY APPLN. INFO.:			US 2000-181799P	P 20000211

AB Described herein is a method for increasing levels of S-adenosylmethionine within the human body without administering S-adenosylmethionine directly. The method of the invention may be achieved by administering one or more of L-methionine, betaine, and malic acid, together with at least one compd. selected from the group consisting of folic acid, vitamin B12, magnesium, calcium, and other cofactors.

=> file hcaplus  
FILE 'HCAPLUS' ENTERED AT 12:19:15 ON 21 APR 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Apr 2005 VOL 142 ISS 17  
FILE LAST UPDATED: 20 Apr 2005 (20050420/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que  
L1 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

L3 5714 SEA FILE=REGISTRY SSS FUL L1  
L8 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (FOOD OR SUPPLEMENT OR  
DIETARY)  
L9 2 SEA FILE=HCAPLUS ABB=ON PLU=ON "HALEVIE GOLDMAN BRIAN D"/AU  
L10 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 OR L9

=> d his

(FILE 'HOME' ENTERED AT 12:07:30 ON 21 APR 2005)  
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:07:43 ON 21 APR 2005  
L1 STR

L2 14 S L1  
 L3 5714 S L2 FULL  
 L4 STR  
 L5 0 S L4  
 L6 STR L4  
 L7 0 S L6

FILE 'HCAPLUS' ENTERED AT 12:13:12 ON 21 APR 2005  
 L8 11 S L3 AND (FOOD OR SUPPLEMENT OR DIETARY)  
     E HALEVIE-GOLDMAN B/AU  
 L9 2 S E2  
     E HALEVIE GOLDMAN B/AU  
 L10 13 S L8 OR L9

FILE 'HCAPLUS' ENTERED AT 12:19:15 ON 21 APR 2005

=> d ibib abs hitrn l13 tot  
 L13 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d ibib abs hitrn l10 tot

L10 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:534284 HCAPLUS  
 DOCUMENT NUMBER: 141:70644  
 TITLE: Antioxidant arylbenzofuranones and other substances for edible fats, oils and **foods** and feeds containing these materials.  
 INVENTOR(S): Seltzer, Raymond; Ravichandran, Ramanathan  
 PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055141	A2	20040701	WO 2003-EP50954	20031208
WO 2004055141	A3	20041209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-434715P	P 20021218

OTHER SOURCE(S): MARPAT 141:70644

AB A combination of one or more compds. selected from the group consisting of 3-arylbenzofuranones, long chain N,N-dialkylhydroxylamines, substituted hydroxylamines, nitrones, and amine oxides is highly effective as an antioxidant for use with edible organic substances subject to deterioration

by oxidation  
 IT 243655-78-9D, esters  
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (antioxidant arylbenzofuranones and other substances for edible fats,  
 oils and foods and feeds containing these materials)

L10 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:495676 HCAPLUS  
 DOCUMENT NUMBER: 141:47382  
 TITLE: Method for enhancing the natural reward system for exercise  
 INVENTOR(S): Halevie-Goldman, Brian D.  
 PATENT ASSIGNEE(S): Fast Balance, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 9 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004116351	A1	20040617	US 2003-730627	20031208
PRIORITY APPLN. INFO.:			US 2002-431255P	P 20021206
			US 2003-468041P	P 20030505

AB Methods of enhancing and prolonging the natural reward system for exercise by administering one or more opiate destruction-inhibitors alone or in combination with one or more neurotransmitter precursors. When people exercise, they can experience a "runner's high" or a state of euphoria, which has been found to be based on natural opioids. By enhancing and prolonging the "runner's high," incentive to exercise and to continue exercising will be increased. Further methods include the addition of any of a number of additives, such as those conventionally used for weight loss and appetite suppression.

L10 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:424683 HCAPLUS  
 DOCUMENT NUMBER: 139:148613  
 TITLE: Immunochemical Determination of 2,4,6-Trichloroanisole as the Responsible Agent for the Musty Odor in Foods. 1. Molecular Modeling Studies for Antibody Production  
 AUTHOR(S): Sanvicens, Nuria; Sanchez-Baeza, Francisco; Marco, M.-Pilar  
 CORPORATE SOURCE: Department of Biological Organic Chemistry, IIQAB-CSIC, Barcelona, 08034, Spain  
 SOURCE: Journal of Agricultural and Food Chemistry (2003), 51(14), 3924-3931  
 CODEN: JAFCAU; ISSN: 0021-8561  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Nine antisera were raised against 2,4,6-trichloroanisole (2,4,6-TCA) by immunizing them with 3 different haptens. With the spacer arm at the meta position, hapten A (3-(2,4,6-trichloro-3-methoxyphenyl)propanoic acid) preserved all of the functional groups of the target analyte. In hapten B (5-(2,4,6-trichlorophenoxy)pentanoic acid), the spacer was placed in the mol. substituting the methoxy group. Finally, hapten C (3-(3,5-dichloro-4-methoxyphenyl)propanoic acid) held the spacer arm at

the para position instead of the chlorine atom of the target analyte. Using theor. models, how the mol. geometry and the electronic distribution are affected by the introduction of the linker was studied. The evaluation of the avidity of the resulting antibodies demonstrates that the orientation produced by the spacer arm must also be considered an essential aspect. The screening for competitive assays performed after synthesizing a battery of heterologous competitors has provided with these antibodies 8 indirect enzyme-linked immunosorbent assays with acceptable properties. From the number of assays obtained, their maximal absorbance, their signal-to-noise ratio, the slope, and the IC50 values obtained, it can be concluded that hapten C provided the best antibodies.

IT 274928-12-0 395545-60-5, 3-(2-Hydroxy-3,5,6-trichlorophenyl)propanoic acid 568579-74-8 568579-75-9  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (immunochem. determination of 2,4,6-trichloroanisole as the responsible agent  
 for musty odor in foods as to mol. modeling studies for antibody production)

IT 395545-65-0  
 RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)  
 (immunochem. determination of 2,4,6-trichloroanisole as the responsible agent  
 for musty odor in foods as to mol. modeling studies for antibody production)

IT 568579-78-2P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (immunochem. determination of 2,4,6-trichloroanisole as the responsible agent  
 for musty odor in foods as to mol. modeling studies for antibody production)

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:221658 HCAPLUS  
 DOCUMENT NUMBER: 138:255237  
 TITLE: Preparation of indole derivatives as DP receptor antagonists  
 INVENTOR(S): Torisu, Kazuhiko; Hasegawa, Tomoyuki; Kobayashi, Kaoru; Nambu, Fumio  
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 210 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022813	A1	20030320	WO 2002-JP9077	20020906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,				

TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1424325 A1 20040602 EP 2002-798037 20020906



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

US 2005004096 A1 20050106 US 2004-488834 20040308

PRIORITY APPLN. INFO.: JP 2001-271281 A 20010907  
WO 2002-JP9077 W 20020906

OTHER SOURCE(S): MARPAT 138:255237

GI



AB The title indole compds., substituted by either dihydrobenzoxazinyl or benzodioxanyl, with general formula of I [wherein R = COR1, CH2OR0, or CO2R20; R0 = H or acyl; R1 = alkoxy or (un)substituted amino; R20 = allyl or PhCH2; R2 = H, (alkoxy)alkyl, alkoxy, halo, NH2, trihalomethyl, CN, OH, PhCH2, or 4-MeO-PhCH2; R3 = H, alkyl, alkoxy, halo, trihalomethyl, CN, or OH; R4 and R5 = independently H, (alkoxy)alkyl, alkoxy, halo, NO2, NH2, trihalomethyl, trihalomethoxy, CN, or OH; D = a single bond, alkylene, alkenylene, or oxyalkylene; G = CONH, NHCO, SO2NH, NHSO2, diazo, (un)substituted alkylene, or alkenylene; R6 = 3-15 membered cyclyl or (un)substituted 4-15 membered heterocyclyl; or G and R6 together form (un)substituted alkyl, alkenyl, or alkynyl; n = 1-3; m = 1-3; p = 1-4] and pharmaceutically acceptable salts thereof are prepared as prostaglandin D2 (PGD2) receptor antagonists. For example, the indole II was prepared in a multi-step synthesis. II showed Ki of 0.031  $\mu$ M against DP receptor in rat. Compds. I are useful in preventing/treating allergic diseases, diseases associated with itch, diseases secondarily caused by behaviors associating itch, inflammation, chronic obstructive pulmonary disease, ischemic reperfusion injury, cerebrovascular diseases, rheumatoid arthritis-complicated pleuritis, ulcerative colitis, etc. (no data).

IT Formulations containing I as an active ingredient were also described.

IT 502433-97-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(DP receptor antagonist; preparation of indole derivs. as DP receptor antagonists)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:247727 HCPLUS

DOCUMENT NUMBER: 136:262299

TITLE: Growth inhibitors for thermophilic spore-forming bacteria

INVENTOR(S): Mori, Terutaka; Ogawa, Toru; Oki, Akira

PATENT ASSIGNEE(S): Lion Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002097105	A2	20020402	JP 2000-323264	20000919
PRIORITY APPLN. INFO.:			JP 2000-323264	20000919

AB The growth inhibitors contain 3,4-dihydroxyhydrocinnamic acid (I) and/or its salts. I (at 0.50 weight%) completely inhibited the growth of *Bacillus subtilis* ATCC9372. Milk coffee beverage showed no growth of *B. stearothermophilus* ATCC7953 after 3-mo storage at 55° following inoculation with the bacteria and mixing with 0.05 weight% I.

IT 405273-86-1

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); FFD (Food or feed use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)

(dihydroxyhydrocinnamic acids for growth inhibition of thermophilic spore-forming bacteria)

L10 ANSWER 6 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:157574 HCPLUS

DOCUMENT NUMBER: 136:210605

TITLE: Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists

INVENTOR(S): Brotan, Theodore P.; Nantel, Francois J.; Metters, Kathleen M.; Turner, Mervyn

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Frosst Canada & Co.

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015902	A1	20020228	WO 2001-US25982	20010820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,  
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2001086557 A5 20020304 AU 2001-86557 20010820  
 US 2002137746 A1 20020926 US 2001-935614 20010823  
 PRIORITY APPLN. INFO.: US 2000-227183P P 20000823  
 WO 2001-US25982 W 20010820

OTHER SOURCE(S): MARPAT 136:210605

GI



AB This invention encompasses a method of treating or preventing urinary incontinence in a mammalian patient comprising administering to the patient a compound of formula I ( $X = C$  or  $N$ ;  $x$  and  $z$  are independently 0-2 such that  $y + z = 2$ ;  $R_a$  = heteroaryl such as furyl, diazinyl, triazinyl, tetrazinyl, imidazolyl, isoxazolyl, isothiazolyl, etc.;  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  are independently = H, halogen, C1-6alkyl, C1-6alkoxy, C1-6alkylthio, etc.;  $R_6$  = H, OH, C1-6alkyl, C1-6alkoxy, etc.) or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses certain pharmaceutical compns. and methods for treatment of prostaglandin mediated diseases comprising the use of compds. of formula I.

IT 330811-47-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists in combination with other agents)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:11098 HCAPLUS

DOCUMENT NUMBER: 136:64168

TITLE: Compositions and methods for the production of S-adenosylmethionine within the body

INVENTOR(S): Halevie-Goldman, Brian D.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002002146	A1	20020103	US 2001-781822	20010212

PRIORITY APPLN. INFO.: US 2000-181799P P 20000211

AB Described herein is a method for increasing levels of S-adenosylmethionine within the human body without administering S-adenosylmethionine directly. The method of the invention may be achieved by administering one or more of L-methionine, betaine, and malic acid, together with at least one compound selected from the group consisting of folic acid, vitamin B12, magnesium, calcium, and other cofactors.

L10 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:791912 HCAPLUS

DOCUMENT NUMBER: 135:344503

TITLE: Preparation of imidazopyrimidines and triazolopyrimidines as inhibitors of Syk tyrosine kinase

INVENTOR(S): Yura, Takeshi; Conception, Arnel B.; Hahn, Kyun Hee; Hiraoka, Makiko; Katsumada, Hiroko; Kawamura, Norihiro; Kokubo, Toshio; Komura, Hiroshi; Lee, Young Ho; Lowinger, Timothy B.; Motegi, Munehito; Yamamoto, Tomoyuki; Yoshida, Osahiro

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Jpn. Kokai Tokkyo Koho, 212 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001302667	A2	20011031	JP 2000-128870	20000428
CA 2407531	AA	20011025	CA 2001-2407531	20010417
WO 2001083485	A1	20011108	WO 2001-EP4357	20010417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1278750	A1	20030129	EP 2001-936242	20010417
EP 1278750	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010404	A	20030211	BR 2001-10404	20010417
JP 2003535067	T2	20031125	JP 2002-500795	20010417
EE 200200606	A	20040415	EE 2002-606	20010417
NZ 522241	A	20040430	NZ 2001-522241	20010417
AT 272639	E	20040815	AT 2001-936242	20010417
NZ 526221	A	20050128	NZ 2001-526221	20010417

ZA 2002007676	A 20030925	ZA 2002-7676	20020925
BG 107166	A 20030630	BG 2002-107166	20021003
NO 2002005154	A 20021025	NO 2002-5154	20021025
US 2004054179	A1 20040318	US 2003-258628	20030214
PRIORITY APPLN. INFO.:		JP 2000-128870	A 20000428
		WO 2001-EP4357	W 20010417

OTHER SOURCE(S): MARPAT 135:344503

GI



AB The title compds. [I; R1 = X-R4, (un)substituted 4- to 5-membered (un)saturated heterocyclyl containing ≤4 heteroatoms selected from O, N, and S, 4 to 7-membered (un)saturated carbocyclyl, 7 to 10-membered (un)saturated condensed ring moiety optionally containing ≤4 heteroatoms selected from O, N, and S [wherein X = (un)substituted CH2, O, S, SO, SO2, (un)substituted NH; R4 = (un)substituted C7-10 aroyl, C7-10 aralkyl, C1-10 alkyl, C2-10 alkenyl, C3-7 (un)saturated carbocyclyl, 4 to 7-membered (un)saturated heterocyclyl containing ≤4 heteroatoms selected from O, N, and S, 7 to 10-membered (un)saturated condensed ring moiety optionally containing ≤4 heteroatoms selected from O, N, and S]; Y = CH, N; R2 = H, (un)substituted C1-10 alkyl, NR8COR9, NR8CO2R9', COR8, CO2R9, CONR8R9 [wherein R8, R9 = H, (un)substituted C1-6 alkyl]; R3 = (un)substituted aryl or heteroaryl] or salts thereof are prepared. These compds. are useful as antiallergic agent for the prevention or treatment of asthma, allergic rhinitis, atopic dermatitis, food allergy, contact allergy, hives, conjunctivitis, and vernal (spring) catarrh, or as immunosuppressants, anticoagulants, or antitumor agents. Thus, 5-chloro-7-(3,4-dimethoxyphenyl)imidazo[1,2-c]pyrimidine, 1-(4-fluorophenyl)piperazine dihydrochloride, diisopropylethylamine, and 2-propanol were heated at 90° with stirring to give 64.6% 7-(3,4-dimethoxyphenyl)-5-[4-(4-fluorophenyl)piperazin-1-yl]imidazo[1,2-c]pyrimidine which showed IC50 of ≤0.5 μM against Syk tyrosine kinase.

IT 371167-31-6P 371167-39-4P 371167-49-6P  
 371167-89-4P 371169-89-0P 371170-93-3P  
 371170-94-4P 371170-95-5P 371170-97-7P  
 371170-98-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of imidazopyrimidines and triazolopyrimidines as inhibitors of Syk tyrosine kinase, immunosuppressants, anticoagulants, antitumor agents, or antiallergic agents)

L10 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:779805 HCAPLUS

DOCUMENT NUMBER: 136:112174

TITLE: Caffeic acid, chlorogenic acid, and dihydrocaffeic

AUTHOR(S): acid metabolism: glutathione conjugate formation  
 Moridani, Majid Y.; Scobie, Hugh; Jamshidzadeh, Akram;  
 Salehi, Par; O'Brien, Peter J.

CORPORATE SOURCE: Faculty of Pharmacy, University of Toronto, ON, M5S  
 2S2, Can.

SOURCE: Drug Metabolism and Disposition (2001), 29(11),  
 1432-1439

PUBLISHER: American Society for Pharmacology and Experimental  
 Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The antioxidant properties of the **dietary** dihydroxycinnamic acids [caffeic (CA), dihydrocaffeic (DHCA), and chlorogenic (CGA) acids] have been well studied but little is known about their metabolism. In this article, evidence is presented showing that CA, DHCA, and CGA form quinoids and hydroxylated products when oxidized by peroxidase/H<sub>2</sub>O<sub>2</sub> or tyrosinase/O<sub>2</sub>. Mass spectrometry analyses of the metabolites formed with peroxidase/H<sub>2</sub>O<sub>2</sub>/glutathione (GSH) revealed that mono- and bi-glutathione conjugates were formed for all three compds. except CGA, which formed a bi-glutathione conjugate only when GSH was present. In contrast, the metabolism of the dihydroxycinnamic acids by tyrosinase/O<sub>2</sub>/GSH resulted in the formation of only mono-glutathione conjugates. In the absence of GSH, hydroxylated products and p-quinones of CA or CGA were formed by peroxidase/H<sub>2</sub>O<sub>2</sub>. DHCA formed a hydroxylated adduct (even though GSH was present), as well as the corresponding p-quinone and dihydroesculetin, an intramol. cyclization product. NADPH also supported rat liver microsomal-catalyzed CA-, CGA-, and DHCA-glutathione conjugate formation, which was prevented by benzylimidazole, a cytochrome P 450 inhibitor. Furthermore, the cytotoxicity of CA, CGA, and DHCA toward isolated rat hepatocytes was markedly enhanced by hydrogen peroxide or cumene hydroperoxide-supported cytochrome P 450 and was prevented by benzylimidazole. Cytotoxicity was also markedly enhanced by dicumarol, an NADPH/oxidoreductase inhibitor. These results suggest that dihydroxycinnamic acids were metabolically activated by P 450 peroxidase activity to form cytotoxic quinoid metabolites.

IT 390417-67-1 390417-68-2 390417-69-3

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL  
 (Biological study)

(caffeic acid, chlorogenic acid, and dihydrocaffeic acid metabolism:  
 glutathione conjugate formation)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:738942 HCPLUS

DOCUMENT NUMBER: 135:262221

TITLE: Topical formulation containing carageenin and a  
 hyaluronic acid salt.

INVENTOR(S): Reiner, Alberto; Reiner, Giorgio

PATENT ASSIGNEE(S): APR Applied Pharma Research SA, Switz.

SOURCE: Patentschrift (Switz.), 7 pp.

CODEN: SWXXAS

DOCUMENT TYPE: Patent

LANGUAGE: Italian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----  
 CH 691030 A 20010412 CH 1995-2728 19950926  
 PRIORITY APPLN. INFO.: CH 1995-2728 19950926  
 AB An aqueous gel formulation for topical use is disclosed which is characterized by the presence of both a low-mol.-weight carrageenin and a hyaluronic acid salt. It has emollient and soothing properties under painful conditions resulting from inflammation of mucosa and epidermis.  
 IT 362013-56-7  
 RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (topical formulation containing carageenin and a hyaluronic acid salt.)

L10 ANSWER 11 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:676748 HCPLUS  
 DOCUMENT NUMBER: 135:242135  
 TITLE: Preparation process of indole derivatives and use thereof as DP receptor antagonists  
 INVENTOR(S): Torisu, Kazuhiko; Kobayashi, Kaoru; Nambu, Fumio  
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 277 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066520	A1	20010913	WO 2001-JP1817	20010308
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2402174	AA	20010913	CA 2001-2402174	20010308
AU 2001041068	A5	20010917	AU 2001-41068	20010308
EP 1262475	A1	20021204	EP 2001-912193	20010308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009050	A	20040427	BR 2001-9050	20010308
NZ 521192	A	20050128	NZ 2001-521192	20010308
ZA 2002007031	A	20030306	ZA 2002-7031	20020902
NO 2002004281	A	20021108	NO 2002-4281	20020906
US 2003176400	A1	20030918	US 2002-220806	20021213
US 6743793	B2	20040601		
US 2004180885	A1	20040916	US 2004-793725	20040308
PRIORITY APPLN. INFO.:			JP 2000-64696	A 20000309
			JP 2000-231857	A 20000731
			WO 2001-JP1817	W 20010308
			US 2002-220806	A3 20021213
OTHER SOURCE(S):	CASREACT 135:242135; MARPAT 135:242135			
GI				



AB A process for preparing title compds. [I; R = 4-O(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, 4-O(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>, 4-O(CH<sub>2</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, 4-O(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, 4-O(CH<sub>2</sub>)<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, 4-O(CH<sub>2</sub>)<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, 4-OCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, 4-(CH<sub>2</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, 4-CH<sub>3</sub>O<sub>2</sub>C<sub>6</sub>H<sub>5</sub>(CH<sub>2</sub>)<sub>2</sub>O, 4-OCH<sub>2</sub>CH<sub>2</sub>OCH(CH<sub>3</sub>)<sub>2</sub>, 4-(4-CH<sub>3</sub>O<sub>2</sub>C<sub>6</sub>H<sub>4</sub>)CH<sub>2</sub>O, 4-O(CH<sub>2</sub>)<sub>2</sub>SCH<sub>2</sub>CH<sub>3</sub>, 4-O(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, 4-OCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, 4-OCH<sub>2</sub>CH<sub>3</sub>, 4-C<sub>6</sub>H<sub>5</sub>, 4-heterocyclcylalkoxy, 3-O(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, 3-O(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>, 4-heterocyclcylcarbonylamino; R<sub>1</sub> = CH<sub>3</sub>, H, CH<sub>2</sub>CH<sub>3</sub>; R<sub>2</sub> = H, OCH<sub>3</sub>, CH<sub>3</sub>; R<sub>3</sub> = H, OCH<sub>3</sub>; R<sub>4</sub> = H, 4-CH<sub>3</sub>O<sub>2</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, CH<sub>3</sub>, CH<sub>2</sub>OCH<sub>3</sub>; R<sub>5</sub> = H, OCH<sub>3</sub>; X = CH<sub>2</sub>, single bond, OCH<sub>2</sub>, CH:CH, CH<sub>2</sub>CH<sub>2</sub>] as DP receptor antagonists are presented. Title compds. I, bind to DP receptor to exhibit antagonism, and therefore are useful in prevention and/or treatment of allergic diseases (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mastocytosis, disorders due to systemic mastocyte activation, anaphylactic shock, tracheal constriction, urticaria, and eczema), diseases accompanied with itching (such as atopic dermatitis and urticaria), secondary diseases caused by scratching, beating or other behaviors attendant on itching (such as cataract, retinal detachment, inflammation, infection, and sleep disorder), inflammation, chronic obstructive lung disease, reflow disturbance occurring after the recovery from the ischemic conditions, cerebrovascular disease, pleuritis complicated by rheumatoid arthritis, ulcerative colitis, and other diseases. Thus, the title compound I (R = O(CH<sub>2</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>; R<sub>1</sub> = CH<sub>3</sub>; R<sub>2</sub> = H) was prepared

IT 359583-64-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation process of indole derivs. and use thereof as DP receptor antagonists)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:356204 HCAPLUS

DOCUMENT NUMBER: 134:361375

TITLE: Use of apo B secretion/MTP inhibitors as antiobesity agents

INVENTOR(S): Hickman, Mary Anne; Lundy, Kristin Marie; Morgan, Bradley Paul

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1099438	A2	20010516	EP 2000-309705	20001103
EP 1099438	A3	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2325282	AA	20010510	CA 2000-2325282	20001108
ZA 2000006417	A	20020508	ZA 2000-6417	20001108
NZ 508061	A	20020426	NZ 2000-508061	20001109
AU 777542	B2	20041021	AU 2000-71519	20001109
JP 2001181209	A2	20010703	JP 2000-344128	20001110
PRIORITY APPLN. INFO.:			US 1999-164513P	P 19991110
OTHER SOURCE(S):		MARPAT 134:361375		
GI				



I

AB The invention relates to methods and pharmaceutical compns. useful in reducing **food** intake in an animal, preferably a mammal including a human subject or a companion animal, using a microsomal triglyceride transfer protein apolipoprotein B (apo B) secretion/microsomal triglyceride transfer protein (MTP) inhibitor. Antiobesity agents may be included in the formulations. I and II reduced **food** intake in dogs by 58% and 30%, resp.

IT 339313-51-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(apo B secretion/MTP inhibitors as antiobesity agents)

L10 ANSWER 13 OF 13 HCPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:83729 HCAPLUS

DOCUMENT NUMBER: 132:250169

**TITLE:** Synthesis of Haptens and Conjugates for ELISAs of Phytoestrogens. Development of the Immunological Tests

AUTHOR(S) : Bennetau-Pelissero, Catherine; Le Houerou, Cyril; Lamotte, Valerie; Le Menn, Francoise; Babin, Pierre; Bennetau, Bernard

CORPORATE SOURCE: ENITA de Bordeaux, Gradignan, 33175, Fr.

SOURCE: Journal of Agricultural and Food Chemistry (2000), 48 (2), 305-311

CODEN: JAFCAU; ISSN: 0021-8561

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Seven carboxylic acid haptens of isoflavonoids were synthesized, with the spacer arm on the oxygen atom at the C7 position for one series, with formononetin, daidzein, equol, biochanin A, and genistein, and at the C8 position for a 2nd series, with only formononetin and daidzein. The different haptens were coupled to bovine serum albumin (BSA) and to swine thyroglobulin (Thyr). Polyclonal antibodies were generated against the BSA conjugates. ELISAs were developed based on competition between free phytoestrogens and the Thyr-hapten conjugates for specific antibodies. IC50 values of the standard curves ranged between 0.8 and 20 ng/mL i.e., 0.3 and 9.2 pmol/well. The antibodies obtained should be useful for assays in vegetable matter as well as in biol. fluids after a separation step. These ELISAs should be valuable also in the food industry to control phytoestrogen concns. prior to and after processing.

IT 262600-99-7P 262601-00-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of haptens and conjugates for ELISAs of phytoestrogens.  
development of immunol. tests)

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT